Understanding cancer treatment options in Japan

Particle therapy uses carbon ions or protons and the Bragg Peak effect to concentrate radiation dose at tumor depth. Institutions such as QST, SAGA HIMAT, and MediProton evaluate suitability based on cancer type, stage, imaging, and prior treatment records; fractions, risks, and expected benefits must be explained by radiation oncologists.

• ・Carbon-ion and proton therapy evaluation
• ・Bragg Peak dose-concentration planning
• ・QST respiratory gating, 3D scanning, and rotational irradiation options
• ・Fractions and risks explained case by case by the hospital

Summarizes public consultation information on photoimmunotherapy, photodynamic, and sonodynamic options from TGC Tokyo Cancer Clinic, Tokyo Cancer Clinic, and Saisei Mirai Group. Irradiation method, depth, fees, risks, and current availability require case-by-case confirmation.

• ・PIT / ICG Liposome availability requires confirmation
• ・External and intravascular irradiation conditions must be checked
• ・ERP / photosensitizer information is technical background
• ・Do not frame as immune-memory or efficacy guarantees

Summarizes consultation information on ECCT low-frequency electric-field adjunctive therapy. Eligibility, combination with standard care, device use, fees, and risks require case-by-case clinic confirmation.

• ・Physical mechanism requires clinic confirmation
• ・Wearable-device use needs confirmation
• ・Explored in research as an adjunct to chemotherapy

Dojin Clinic’s six-cell combination uses helper T, killer T, γδT, NK, NKT and dendritic cells. The clinic assesses suitability, blood collection, autologous-cell culture, fees and coordination with existing treatment from the medical records.

• ・Six-cell combination at Dojin Clinic
• ・Autologous-cell collection and culture
• ・Physician review of eligibility and combinations

NK-cell and BAK information concerns immune-cell approaches involving autologous-cell collection, culture and infusion. Cell types, preparation and availability differ by institution. Eligibility, risks, fees and follow-up require review of the medical records.

• ・Autologous immune-cell collection and culture
• ・Confirm BAK availability with the institution
• ・Review infusion plans, risks and follow-up

Tumor mutation analysis helps identify candidate neoantigens for personalized vaccines. Testing, peptide preparation and administration vary by institution. Fukuoka Cancer General Clinic uses this approach in dendritic-cell vaccines, subject to specimen, feasibility and eligibility review.

• ・NGS and AI analysis may support physician evaluation
• ・Suitability for a personalized approach must be reviewed by a physician
• ・Research background and current availability require case-by-case confirmation

Ginza Ichome Clinic describes Hybrid MAT as a plant-derived IAF immune-modulator approach combined with supportive oral ARL. Saisei Mirai Group describes GcMAF specimen analysis and blood-derived preparation. These are self-pay treatment materials and require confirmation of current availability, testing flow, fees, and relationship with standard care.

• ・Hybrid MAT and GcMAF details should be confirmed separately
• ・Specimen analysis and preparation flow require review
• ・Self-pay and supportive-care consultation

Summarizes cancer gene-therapy consultations described in partner-clinic public materials, including Gankyrin-silencing RNA, TRAIL, CDC6shRNA, p16, and JG-1. Current availability, eligibility, fees, risks, and relationship with standard care must be confirmed case by case with the receiving clinic.

• ・Tumor-suppressor injection consultation
• ・Gankyrin-silencing RNA consultation
• ・TRAIL / CDC6 targets require case-by-case confirmation
• ・JG-1 and vector information require case review

Summarizes Hasumi Clinic public consultation information on Hasumi vaccine, HITV, preHITV, and immune-cell therapy. History, case numbers, and technical background may be cited as clinic material, but not as guarantees of efficacy, low side effects, or eligibility.

• ・Hasumi vaccine history and case counts are background only
• ・Side effects and follow-up require confirmation
• ・Cancer type and patient eligibility require physician review

Dendritic cells present antigens. These vaccine approaches use patient-derived cells and selected tumor antigens. Antigen selection, cell culture and administration differ by institution; one clinic’s technique should not be assumed to apply to all. Goals, risks and eligibility require individual review.

• ・Tumor-marker information should be explained by the institution
• ・Immune response and suitability require case-by-case review
• ・Blood draw volume and physical burden must be confirmed by the physician

Fukuoka Cancer General Clinic cultures lymphocytes from the patient’s blood, mainly activated T cells and NK cells. This is distinct from six-cell combination therapy. Collection, infusion, fees and coordination with standard care are explained case by case.

• ・Activated T cells and NK cells
• ・Fukuoka Cancer General Clinic
• ・Self-pay; individual assessment